eurofins corporate december 2014 hva debt investor · 2017-07-18 · eurofins a global leader in...

www.eurofins.com

EurofinsA global leader in bioanalytical testing in the food,

environment and pharmaceutical sectors

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay 1

Debt Investor PresentationJanuary 2015

Source presentation EDR: 1-C-IR-PRE-01187643Source modification date: 07/08/2014

2

Disclaimer

The statements made during this presentation or as response to questions during the Question & Answers period that arenot historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on marketand competitive information available at a certain time. Forward looking statements and estimates represent the judgementof Eurofins Scientific’s management and involve risks and uncertainties including, but not limited to, risks associated with theinherent uncertainty of research, product/ service development and commercialisation, the impact of competitive productsand services, patents and other risk uncertainties, including those detailed from time to time in period reports, includingprospectus and annual reports filed by Eurofins Scientific with the Luxembourg Stock Exchange and regulatory authorities,that can cause actual results to differ materially from those projected. Eurofins Scientific expressly disclaims any obligationor intention to release publicly any updates or revisions to any forward looking statement or estimate.

In addition, Eurofins provides in the Income Statement certain non-IFRS information (“Adjusted Results and SeparatelyDisclosed Items”) that excludes certain items because of their nature and the impact they have on the analysis of underlyingbusiness performance and trends. (Please refer to description of these terms in the Company’s Annual Report). Themanagement believes that providing this information enhances investors' understanding of the company’s core operatingresults and future prospects, consistent with how management measures and forecasts the company’s performance,especially when comparing such results to previous periods or objectives and to the performance of our competitors. Thisinformation should be considered in addition to, but not in lieu of, information prepared in accordance with IFRS.

This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for orpurchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall formthe basis of, or be relied on in connection with, any offer or commitment whatsoever.

Analyst forecasts quoted are based on published analyst views. They are the responsibility of the investment banks whichpublish those forecasts and should not be interpreted as representing the views or expectations of Eurofins Scientific or theEurofins Scientific management. In particular, they do not constitute a profit forecast or estimate or trading statement byEurofins Scientific S.E. Similarly, objectives presented are only objectives and may not be achieved in reality, potentially by awide margin, due to a variety of factors.

Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay


3

� Introduction

� Market & Strategic Positioning

� Finance & Outlook

� Transaction Overview

� Summary

� Appendix

Contents



4

Eurofins’ Mission is to contribute to globalHealth, Safety & Environment with the best in bioan alysis

� Founded in 1987� IPO in 1997 in Paris at EUR 1.83 per share� Network of more than 200 laboratories in

36 countries� Over 100,000 reliable analytical methods� Over 16,000 employees� Simplified shareholder structure: Martin

Family 42.7% of share capital (59.5% of voting rights); Free float 57.3%

Key figures 2013 2008-2013 CAGRRevenues EUR 1,226m 14%EBITDA EUR 189m 19%Net Profit EUR 72m 32%

*Adjusted– reflects ongoing performance of the mature and recurring activities excluding “separately disclosed items”

Food

Environment Pharmaceuticals

Eurofins provides testing services in three main areas that have a strong impact on

human health:

“Recent trends in global food production, processing,distribution and preparation are creating an increasingdemand for food safety research in order to ensure asafer global food supply.” World Health Organisation

EUROFINS 2017: Mid Term ObjectivesEUR 2bn Revenues (13% CAGR from 2013)

>20% Adjusted EBITDA Margin



Market size estimate ~ EUR 4bn

*To the best of Eurofins’ knowledge, based on data available to the Group

~ EUR 2.0bn ~ EUR 5bn

N°1*worldwide

N°1 to N°3* worldwide

Testing forTesting forTesting forTesting forPharma/Pharma/Pharma/Pharma/BiotechBiotechBiotechBiotech Environment Environment Environment Environment

TestingTestingTestingTesting

Food & Food & Food & Food & Feed Feed Feed Feed

TestingTestingTestingTesting

N°1*worldwide

Eurofins ranking

N° 1 in EuropeN° 1 in Germany N° 1 in France N° 1 in ScandinaviaN° 1 in BeneluxN° 1 in the UK**N° 1 in BrazilN° 2 in the USA**N° 1 in Agri Testing EU

N° 1 in Europe N° 1 in GermanyN° 1 in FranceN° 1 in ScandinaviaN° 1 in Benelux

N° 1 Worldwide in Pharma Product TestingN° 1 Worldwide in Discovery Pharmacology ServicesAmong top 3 global providers of central laboratory, genomic and agrosciences servicesN° 1 or 2 in most segments/countries in Europe

** except routine Bacteriology - focus on high end a nalysis

Leading global and local market positions

New!

New!

5Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay


6

Demand for safe pharmaceuticals, quality food

and clean environment

Risks linked to global sourcing

and brand vulnerability

Consolidation of the fragmented laboratory

market and scale effects

Drivers for long-term market growth

Outsourcing of internal laboratories by industry

One-stop shopping (focus on few global testing suppliers)

Increasing wealth and quality of Life

Technological progress

Advancing globalisation

New analytical methods and lower

detection limits

Consumer expectations for

protection

Secular Underlying Fundamentals General Market Drivers Laboratory Market Drivers



7

An international network of world class, standardis ed laboratories is attractive for our customers

80% of the world’s population still has limited access to testing laboratories

N. America 22.7%

Germany 17.5%

France 17.0%

Others 14.6%

Nordic Region 11.9%

Benelux 10.9%

UK & Ireland 5.4%

H1 2014 revenue split :

Entry into high-growth markets with start ups

& acquisitions



8

Strong growth fueled by market growth, share gains and acquisitions

* Company objective

-

200

400

600

800

1,000

1,200

1,400

1,600

1,800

2,000

1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014* 2017*


CAGR10yrs 22%

CAGR5yrs 14%

RE

VE

NU

ES

EU

R m


9

On track towards 2017 objectives

Eurofins 5 year Report Card: 2008-2013 CAGR

Achievements in 2013

� Over 6.5% organic growth versus 5% objective

� 24% increase in adjusted EBITDA

� More than 10 acquisitions withcombined revenues of ca. €120m

� 26% increase in operating cash flows


2014: second year of our 5-year journey

9M 2014

� 18.6% revenue increase in Q3 to EUR 370m brings revenues for 9M 2014 to over EUR 1 billion, a 14.9% increase from 9M 2013, over 6% of which was organic (over 8% excludingcompanies in significant restructuring).

� 14 acquisitions in 9M 2014 for total annualisedrevenues in excess of EUR 150m.

� Sustained operating momentum in the group’s largest markets

HY 2014

� 17% increase in adjusted EBITDA, translating to 60bp margin expansion in H1 2014

� Stable profits despite peak in one-off costs

YTD 2014

� On track to deliver ca. 40,000m 2 of the 100,000m 2

of modern lab surface planned between 2014-2016 by the end of this year.

� Entry into specialised, genomics-baseddiagnostic testing market via the acquisition of ViraCor-IBT*

*Acquired on 01 July, 2014


10

Eurofins’ strategy aims at building long lasting competitive advantages

� Extensive expertise in local regulations for all major markets, and one-stop contact for compliance in multiple countries

� Globally reliable standards of high quality and consistency

� International key accounts management

� Internet-based transactions and access to testing results

� Competence Centres & R&D activities

� Proprietary technologies for proof of origin, virus phenotyping & authenticity testing

� Continuous development/acquisition of advanced technologies

One stop shop

Leading technology

Pure-play laboratory operator

� International network with a presence in 36 countries

� Vast technological portfolio with more than 100,000 reliable methods

� Over 100 million assays performed per year

� But one contact person for each customer

� Industrialised processes

� Unrivalled expertise accessible to all customers

� Continually expanding geographical coverage

� Proven operating model that can be rolled-out in various/multiple markets

Quality of customer service



11

� Introduction




� Summary

� Appendix

Contents



12

Consumers’ increasing awareness and demand for safe and high quality food

The Food testing market has robust growth drivers

� Compels industry to strengthen its testing programs

� New products (GMOs, new packaging, etc.) create nee d for new tests

� Governments increase regulations on food control

� Brands have become more global and vulnerable to co ntaminations

� Transparency and traceability are becoming the prio rities

� Increasing pressure on producers and manufacturers to invest in testing

Food scares and crises, widely covered in the

media

Demand for a high quality, state-of-the-art, intern ational network of laboratories

Globalisation: Raw materials sourced

from countries with different QC

practices

Outsourcing of industry’s

internal or state-owned

laboratories



13

Retail & Distribution

Eurofins’ Food & Feed testing offering is the most comprehensive in the market

Agricultural production, product

development Production

Dioxins Veterinary drug residues

Organic residues POPs

Heavy metals Irradiation

Quality ControlVitamins

GMOLabelling

PurityNutritional

Microbiology Sensorial

Authenticity Pesticides

Mycotoxins Allergens



14

Year Brand/ Contamination Impact CostCountry

Salmonella in tomatoes and peppers

2008

E. Coli in cookie dough

70 people sick, 25 people hospitalized, job losses, withdrawal of 86 million "cookies-worth”, court proceedings initiated

50,000 infants ill, 6 deaths, global recall of dairy and related products, criminal charges in China

Melamine in dairy products

Sanlu/ Fronterra + global brands

~ USD 100-250m

Unquantified

2009

About 1,500 people sick throughout US & Canada – pulling of products from shops & restaurants

2008

Nestlé

North America/ Mexico

Dioxins Recall of Irish pork products, job losses, destruction of 100,000 pigs

2008

FreshPlaza

CNN Health

BBC News

Irish pork > EUR 300mIrish Exporters Association

Salmonella in peanut butter

2008 ~ USD 100m

Est. only for Kellogg’s

9 dead, 683 people sick, global recall of peanut butter and related products (1,600 types of products involved)

Kellogg’s, Unilever, General Mills

Bloomberg

High profile food scares have expensive consequence s for producers…

Dioxins in eggs, poultry and pork

About 3,000 tons of feed contaminated with oil inte nded for use in bio-fuels, 4700 farms closed, revenues l ost, tightening regulation

2011 Germany BBC news

Beef products contaminated with horse meat

Sales of frozen burgers plunged 43% and frozen ready meals fell 13% in the UK between 21 Jan –17 Feb, 2013, at the height of the scandal

2013 Europe The Guardian

~ EUR 360m

Market value lost for Tesco



15

…and destroy market value

48% drop in share price in first week.

Threat of multiple law suits.

Over 100 brands & over 60m cans of recalled product.

The largest customer (11% of sales) has suspended orders (thought to be WalMart).

Direct cost estimated at US$ 42m

2007 example: Menu Foods is the largest maker of we t cat and dog food in N. America

Melamine contamination of pet foods due to illegal use of a plasticiser in wheat and rice gluten raw material supplies from China.

Tens, possibly hundreds of pets died

- 48%

In the wake of the scandal

drop in orders resulting in a $3.6m loss in the Q2 vs a $2.6m profit in Q2/2006

- 44%

Source: http://www.lapresseaffaires.com

Contamination Direct impact Indirect impact

In fact, this was the same type of contamination to affect baby milk one year later.



16

Horsegate: A reminder of the need for more systemat ic testing

Horsegate Timeline

Dec 2012 Irish authorities become aware of the adulteration in ABP Food Group burgers with 29% horse meat content

Jan 2013 Eurofins Germany confirms to FSAI presence of horsemeat on samples tested from Tesco, Asda, Iceland, etc.

Tesco market value declined EUR 360m*

Feb 2013 EU Commission launched coordinated control testing for presence of horse DNA and phenylbutazone.

Mar 2013 Of the 4,144 tests done to detect horsemeat, 193 tested positive (4.7%)

Of the 3,155 tests done to detect phenylbutazone residues, 16 tested positive (0.5%)

Large food manufacturers and retailers caught up in the scandal identified weaknesses in their supply chains. The official results confirm that only a sufficient level of SYSTEMATIC TESTING across the food supply and production chains can reduce risk and prevent similar scandals

http://ec.europa.eu/food/food/horsemeat/timeline_en .htmhttp://en.wikipedia.org/wiki/2013_meat_adulteration _scandal#cite_note-idsum-55

EU CommissionWikipedia

* The Independent, 16 January 2013


Eurofins’ response to aid the industry

� Rapid capacity scale-up by allocating more of its DNA-testing resources to food analysis, and in particular, meat speciation

� Launch of relevant meat speciation and contamination test-packages

� Industry-beating accuracy and Turn-Around-Time (TAT)

� Developed new protocols based on the latest Next Generation Sequencing (NGS) technologies to increase its DNA-testing capacity and significantly reduce the cost per analysis.

� Eurofins reduced its prices for DNA analysis for meat testing during the crisis to reduce the cost to allow the industry to not only comply with regulations, but systematically manage the risks in their supply chain.


17

Eurofins is meeting the demands of global players

� The largest global food & beverage producers and re tailers are clients of Eurofins

Food and Beverage Retailers2013 Sales in EUR billion

2013 Sales in EUR billion

Nestlé Switzerland 74.9Unilever UK /Netherlands 49.8PepsiCo USA 48.8Coca-Cola USA 34.4Mars* USA 25.0Danone France 21.3McDonalds USA 20.6Kraft Foods* USA 13.4Kelloggs USA 10.9Pernod Ricard France 8.6* estimates

Wal-Mart Stores USA 347.6Carrefour France 84.3CostCo USA 77.3Tesco UK 76.3Kroger USA 72.3Metro AG* Germany 65.4Aldi* Germany 57.0Lidl * Germany 56.7Casino Guichard France 48.6ITM Enterprises France 39.9



18

The Pharma testing market is both healthy and full of potential

� The increasing complexity of clinical trials leads to increasing amounts of diagnostic procedures performed per pate nt

� Regulatory bodies (e.g. FDA) are demanding more stu dy data to improve safety

� Clinical trial processes are becoming increasingly rigorous to ensure drug efficacy

� The spend per drug trial is rapidly increasing

Need for big pharma companies to expand new drugs pipelines

Rapid technological change & increasing complexity in testing require ongoing investment in technology & expertise

Greater trial complexity & size will increase likeli hood of using CROs



19

Underlying trends are in tact for continued growth

� Large pharmas need to refill their product pipeline as the ‘blockbusters’ start to come off patent

� Drug development expenditures have increased substantially in recent years

� Total R&D is over USD 120bn and is expected to further increase

� Sponsors outsource drug development to:- Reduce their fixed cost base- Access competencies that they do not have in-house- Access experience and regulatory expertise in new geographies

� Growth of biotechnology industry:- Limited physical infrastructure- Lack of internal expertise

Source: Citigroup Research 18 Feb, 2014

Source: Citigroup Research 18 Feb, 2014

Global Drug R&D Spending (US$ bn)

Total R&D Spend$ 140 bn

Portion that could beoutsourced

$ 80bn

Currently Outsourced

$34bn

Global % R&D Outsourced



20

Eurofins Pharma Services: 6 activity groups

Genomics DiscoveryPharmacology

Pre-clinical / Early

Development

Clinical (Central

Laboratory)

PharmaProducts Testing /

cGMP QC

Registration

SequencingOligonucleotidesPharmacogenomicsTranscriptomicsGenotypingSNP-analysis

PharmacologyBioanalyticalanalysisTranslationalmedicinePhase I studies

BiomarkersBioanalysisImmunogenicityProteomicsMicrobiological and Anti-infectiveanalysisBioavailabilityBioequivalence

Impurities AnalysisStability StudiesProcessdevelopmentHygiene MonitoringPackaging analysis

Regulatory/Biocides/Chemicals/Agro-chemicals/ Ecotoxicology/Registration/REACH...

Phases

I - III Registration

Phase IV,

Surveillance, Quality Control

Basic Research, Discovery,

Combinatorial,

Biological Product Libraries, etc

Pharmacology, Exploratory

Toxicology, PK, Metabolism, etc

High-throughput-screeningMolecular-pharmacologycell-based assaysin vitro screeningin vitro profilingin vivo safetyin vivo efficacy

Spanning the entire drug development cycle



21

The Top 10 largest global pharmaceutical companies are all clients of Eurofins

Top 10 pharma companies

Pfizer

Sanofi Aventis

GlaxoSmithKline

Novartis

AstraZeneca

Merck & Co

Johnson & Johnson

Roche

Eli Lilly & Co

Bristol-Myers Squibb

Country

USA

France

UK

Switzerland

UK

USA

USA

Switzerland

USA

USA

Global CRO Market

USA 60%

Europe 20%

Japan 8%

Rest of World 12%

Market

BreakdownCAGR*

12%

9%

18%

14%

Source: William Blair &Co.

* 2007 – 2012est.



22

� Increasing demand by citizens for a clean environmen t

� EU expanding regulation (e.g. REACH)

� Increasingly long list of products identified as to xic

� Requirement for more sophisticated analyses and mor e expensive equipment

The Environmental testing market continues to grow

Rise in contamination & pollution issues

Progress in epidemiology & medicine has identified more compounds as toxic

Compels industry to increase testing and outsource internal labs



23

� Outdoor pollutants� Indoor and ambient

pollutants

Eurofins serves all the main environmental testing markets

SOILAIRWATER

Eurofins is the No.1 environmental testing service provider in the world*

� Drinking water and groundwater analysis

� Full range of contaminants

� Analysis of soil for full range of contaminants

Consulting and sampling companies are natural partners

Lancaster Environmental Testing is the laboratory of choice for Fortune 500

companies in the USA

* Management estimate based on available informatio n



24

Global trends in regulation support the business

� Strong regulated markets (EU, USA) are still amending and adding regulations

� Eastern European rules catching up with EU

� Fast development of regulation in Asia

� Regulation used for support of trading blocks (e.g. EU, NAFTA, ASEAN)

� European Food Regulation (EC)178/2002

Recently passed

� European REACH directive� US Country of Origin Labelling (COOL) law� PRC Food Safety Law in China� Food Safety Modernization Act (FSMA) in

USA

In the pipeline

� Comprehensive Review of Food Labelling Law and Policy in Australia & New Zealand

� Food imports

� Labelling (e.g. allergen, origin label, reference intakes)

� Foodstuffs (marketing standards for beverages, meat, fish, dairy products)

� Pesticides

� GMO & GM products

� Additives (vitamin & mineral fortification, flavourings, sweeteners, enzymes)

Key areas of food regulationMajor pieces of legislation



25

*Registration Evaluation and Authorisation of Chemicals(1): Regulation (EC) N° 1907/2006 and Directive 2006/121/EC of the European Parliament and of the Council

Metals, resins, acids, solvents, oils, fibres in textile, car

components, toys, cosmetics, plastics, rubber,

microchip, etc.

Food and drug ingredients are excluded

EU regulations a key driver for the testing industr y – e.g. REACH directive

� Listing and assessing the safety of 30,000chemical substances used by industries in Europe over 11 years

� Replacing the most dangerous ones - no chemical safety studies were conducted before 1981; only 3700 new chemicals analysed up to 2008 out of 100,000 used currently in EU

Time line

Physico-chemical properties: density, viscosity, etc.

Toxicity: skin, eye, mutagenicity, inhalation, oral,

reproductive

Ecotoxicity: invertebrates, plants, fish, birds, soil,

water, degradation

Increasing testing requirements from 2010

Objectives Examples of affected products or industries

Type of testing

Estimated cost

EUR 10bn according to the EU including EUR 1.5bn for testing over 11 years

> 1 t/ p.a.

production

> 100 t/ p.a.

production> 1,000 t/ p.a. production +

substances of very high concern

Nov 2010 May 2013 May 2018Deadlines for

registration



26

Outsourcing adds to market growth Examples of laboratories outsourced to Eurofins

Danish Hydrology Inst. Official water reference lab S candinavia

Suez/Sita Envirolab The Netherlands

Danish farmers association Steins’ water/environment laboratory Denmark

Southern Water Water testing laboratory UK

Lyon University Hospital Phase I Activity France

Austrian Research Institute Food testing Austria

Clermont University Mineral water analysis France

Raisio Group Food product testing Finland

Mondi Environmental, paper/pulp testing Slovakia

DLG Group Food and feed producer Denmark

Miljølaboratoriet Environmental testing network Denma rk

BASF/QTA Environmental, chemicals USA

MWH Global Environmental, water-testing USA

TÜV SÜD Dioxin Analysis Germany

Cranswick plc Food testing UK

Danone Infant and clinical nutrition analysis Germany

Company Outsourced Activity Country



Laboratory Network Investments (1/2): Greenfield projects in high-growth markets

Food

Food, Pharma, Env

Env

Food

Ireland

Spain

Portugal

Netherlands

Food, Pharma

Pharma, Food

Food, Pharma

Food Brazil

Food

Agroscience

Food

Agroscience

Agroscience

Poland

Hungary

Czech Republic

Bulgaria

Romania

China

India

Japan

India: Food Lab profitable in year 2 of start-up

Japan: Radioactivity lab set up; and profitable in year of establishment. Strong start in Environment testing

Brazil: Food Testing profitable;Microbio MAPA audit passed

Eastern: New labs in CZ Republic and Europe Poland

Ireland: Through Lancaster acquisition market leadership position in PPT 1

reached

France: Through IPL acquisition marketleadership position reached in Environment & Water testing

Eurofins’ start-up businesses in aggregate became profitable in 2013

Operational achievementsCountry Market

Europe

Americas

Eastern

Europe

Asia

27

1 Pharma Product Testing

US Food - Microbiology



Laboratory Network Investments (2/2): Expand / modernise laboratory sites

� 80 new/expanded modern state-of-the-art sites to en able consolidation /

closure of smaller or old sites

� Total of ca. 240,000 m 2 added or brought to most modern standards

between 2005 – 2013 (40,000 m 2 in 2013 alone)

� 100,000 m2 of additional modern laboratory surface planned for 2014-2016,

of which over 40,000m 2 planned to come on stream in 2014 alone

Kalamazoo

Vallensbaek

Hamburg

Les Ulis

Saverne

Acton

Singapore

2006 - 2008 2009

Holsterbro

Lidköping

Rotterdam

Cuneo

Washington

Huntsville

Suzhou

Nantes

Denver

Princeton

Vejen

Malbork

Major facilities : new or recently upgraded and pla nned for 2014-2016

Niefern

Ebersberg

Sao Paolo

2010

Cologne

Barneveld

Des Moines

Shanghai

Shenzhen

Tokyo

Nantes (Micro)

Ebersberg ext.

2011

Wolverhampton

Saverne, FR ext.

Glostrup, DK

Melbourne, AU

Monrovia, CA

Garibaldi, BR

Mikkeli, FI

2012 2014-2016

Romsey, UK

Freiberg, DE

Hamburg, DE ext.

Reichenwalde,DE

Vejen, DK ext

Uppsala, SE

Bangalore, IN

New Orleans, LA

Louisville, KY

St. Charles, MO

Aix-en-Provence, FR

Nantes, FR ext

Saverne, FR ext

Douai, FR ext

Les Ulis, FR ext

Moss, NO

Dungarvan, IE ext

Lancaster, PA ext.

Auckland, NZ ext

Yokohama; JP ext

Hamburg, DE ext.

Lancaster, PA ext.

Seattle, WA

Vergeze, FR ext.

Graauw, NL

Wageningen, NL

2013



Market Share: Eurofins is the leader in its industr y –and we continue to reach new market leadership posi tions

New Markets

= Market Entry

Denmark: Food and Env.

Brazil: Food Testing

France Environment

USA: Pharma Products Testing

Sweden, Norway: Food and Env.

Europe: Agroscience, Genomics

Japan: Genomics

Italy, Poland, Austria, Slovakia

Agri Testing Europe

Hungary, Finland

China, India, Singapore, Japan Environment

Australia, New Zealand

Global: Discovery Pharmacology

X No 1

2001 2002 2003 2004 2005 2006 2007 2008

Eurofins already has long-standing no.1 or no.2 posit ions in its main markets: Germany (Food + Env.), France (Food), Benelux (Food + Env. + Central lab)

2009 2010 2011 2012

No 1

X No 1

X No 1

X No 1

X No 1

X No 1

X No 1/3

X

X

X

2013

X

X No 1

X

X

No 1

2014

29Title: Eurofins Corporate Presentation H1 2014 Document name: H1 2014.ppt EDR: 1-C-IR-PRE-01187643 Document owner: Pamela Antay


30

Eurofins’ strategy builds high Barriers to Entry

� GLP� GMP� GCP

ISO 9001ISO 17025

FDA Approved

Offering a premium quality service … ... and leveraging internal efficiencies

� Portfolio : over 100,000 reliable methods –unique in the world and ahead of competition

� Global laboratory network : fully set up for cross-selling worldwide to customers

� Accreditations : multiple international accreditations

� One-stop shop : single point of contact for compliance to regulations of many countries

� Standardised testing in 36 countries

� Sales and marketing : international teams plus dedicated key account management

� Reputation : high standards of quality and consistency - the Eurofins brand

� Internet : web-based transactions and online access to testing results increase switching costs

� Industrialising the laboratory process: rationalisation of sites and personnel

� Competence Centres : high volume laboratories providing highest levels of expertise and service

� Technology : the latest available in the market providing the most accurate results

� Economies of scale in Group purchasing and sales functions

� IT systems : cross-Group information tools and standardised production systems



31

� Introduction



�Transaction Overview

� Summary

� Appendix

Contents



32

� Start-ups: 17 start ups between 2006 and 2010

� Typically losses in years 1 and 2 of about EUR 1-2m p.a. per start-up

� Initial Capex EUR 1- 3m per lab (e.g. premises, equipment)

� Upgrade existing laboratories: ca. EUR 440m invested in additional capital in 2006-2013

Heavy investment in new markets and resources for future profits

� Deploy IT systemseLIMS, eCommerce (EOL)

� Best practice lab organisation & processes

� Consolidation into large, world-class sites

� Standardised testing procedures

� Invest in state-of-the-art technology

Under development perimeter

Bringing recently acquired labs to group

standards

Building corporate resource for future size

and growth

� Recruitment of top leadership

� Additional layer of management to lead global business lines

� Central IT systems and processes(e.g. ERP, CRM)

� Additional central cost+EUR 13m 2010 vs 2005+EUR 13m 2013 vs 2010



33

Selective acquisitions to consolidate and secure leadership of our markets

Lancaster Laboratories (US, Europe, 2011)

IPL (France, 2011)

Nihon Kankyo (Japan, 2012)

Pan Labs (US, 2012), Cerep (France, 2013) and DDS Millipore (US, 2014)

NZ Labs (NZ, 2012) and mgt-Labmark (Australia, 2013)

Danone CLF (Germany, 2013)

Applus Agrofood Testing (Spain, 2014)

ViraCor IBT (USA, 2014)

Anatech (Brazil, 2014)

� Global market leadership in pharma products testing

� Leading position in water testing in France

� Leading position in environment testing in Japan

� Create world leader in Discovery Pharmacology

� Strengthen Asia Pacific footprint

� Outsourcing for infant nutrition analysis, demonstrating Eurofins capabilities

� Leading position serving the Spanish food & retail industry

� Leveraging Eurofins’ genomics testing capabilities to expand into new market segment

� Reinforces Eurofins’ footprint in one of the world’s fastest-growing environmental testing markets

Selected recent transactions Rationale/impact


� In 2013: >10 acquisitions with annual turnover ca. EUR 120m� In 9M 2014: 14 acquisitions with annual turnover > EUR 150m

On 8 December 2014, Eurofins has signed a definitive agreement to acquire Boston Heart Diagnostics Corporation(closing expected to occur early 2015)


34

Positive trends drive solid operating results

Adjusted – reflects the ongoing performance of the mature and recurring activities excluding “separately disclosed items”.LTM – last twelve monthsSeparately disclosed items – includes one-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs, temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring, non-cash accounting charges for stock options, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions and the related tax effects.

HY 2014 HY 2013+/- %

Adjusted

ResultsEURm

Adjusted

Results

Separately

disclosed

items

Statutory

Results

Adjusted

Results

Separately

disclosed

items

Statutory

Results

Revenues 643.5 643.5 570.3 570.3 12.8%

EBITDA 109.0 -18.0 91.0 93.1 -14.8 78.2 17.1%

EBITDA Margin (%) 16.9% 16.3% 60 bp

EBITAS 76.3 -23.0 53.2 66.2 -19.4 46.8 15.2%

Net Profit 48.9 -26.3 22.6 45.2 -22.7 22.5 8.28%

Basic EPS 3.24 -1.75 1.50 3.02 -1.52 1.51 7.3%

Capex 56.9 43.0 32.4%

Op. Cash Flow 47.4 54.7 -13.3%

Net Debt 485.7 381.5 27.3%

Net debt/ LTM

Adjusted EBITDA

2.07x 1.94x NA



Growth and Profitability are critical objectives

� 3-tiered margin support towards mid-term profitability objective

1. Start of profit contribution from start-ups

2. Proportion of companies in restructuring becoming smaller compared to the size of the Group (11.7% of total Group revenues in H1 2014 versus 12.3% in H1 2013)

3. Investments in large industrialized laboratories unlock operational leverage

� A target “cruising altitude” of >20% adjusted EBITDA margin, in addition to top line growth should ensure continued earnings and cash flow growth

35

Group Profitability Objectives ++

*E – company objectives ++ Based on stated company objectives and assumes linear acquisitions 2013-2017

10%

12%

14%

16%

18%

20%

22%

0

500

1,000

1,500

2,000

2,500

2011 2012 2013 2014E* 2017E*

Gro

up

Ad

just

ed

EB

ITD

A m

arg

in %

Gro

up

Re

ve

nu

es

Revenues from start-ups and companies in significant restructuring Mature Revenues



� EUR 300m hybrid bond (of which EUR 150m tap in July 2014 at 5% yield to call date (YTC))

� non-dilutive bond with perpetual maturity, callable at par by Eurofins in Jan 2020

� interest: fixed coupon of 7.00%* until first call, Euribor 3m + 818 bp thereafter if not called

Hybrid

OBSAAR

� issued June 2010

� maturity: EUR 176m across June 2015, 2016, 2017

Solid Balance Sheet

3.5 x� Net Debt/ LTM Adjusted EBITDA

Dec’13Jun’14

2.07 x

Maximum

� Net Debt (EUR m) 386.8

36

Net Debt calculation

Short-term borrowings

+ Long-term borrowings

- Cash & cash equivalents

= NET DEBT

� Total Equity (EUR m)

� EUR 170m issued in July 2011

� 5-7 year maturity; mid-swap or Euribor 6m + spread of 180-220 bp respectively

Schuldschein

1.76 x

485.7

404.3

� Cash + cash equivalents (EUR m)

297.3378.4

394.7

� EUR 300m Eurobond issued in November 2013

� Five-year maturity (Nov 2018) at an annual interest of 3.125%

Eurobond


lower effective cost of hybrid capital as second tranche was issued at lower YTC

*


2.08 x

1.86 x1.94 x

2.07 x

0.00 x

0.50 x

1.00 x

1.50 x

2.00 x

2.50 x

3.00 x

3.50 x

H1 2011 H1 2012 H1 2013 H1 2014

37

High Degree of Financial Flexibility

37

Net Debt/ LTM Adjusted EBITDA: max 3.5x

� Debt ratios remain well below covenant limits* despite EUR 147m** cash invested in the business in H1 2014 (EUR 215m cash in 2013) .

� Largely capex and acquisitions which did not fullycontribute yet in H1 2014.

� Large financial flexibility with fairly long debtmaturity

�OBSAAR issued in 2010; avg. maturity 2016�Schuldschein issued in 2011; avg. maturity 2017�Hybrid capital of EUR 300m; perpetual, callable 2020�EUR 300m Eurobond issued in 2013; maturing 2018�Extension and renewal of credit facilities

� Continued profitability improvement means that key debt ratios have remained stable despite an increase in absolute amount in Net Debt to EUR 486m from EUR 387m in December 2013.

Substantial headroom in the balance sheet


* NB: Gearing covenant no longer applicable

** EUR 147m cash investments = EUR 56.9m capital exp enditures + EUR 72.1m in acquisitions + EUR 18m one-off restruc turing costs and temporary losses

37


� EUR 864m of gross senior debt as of 30 June 2014 (n et debt of EUR 485.7m)

� More than 95% of senior debt located in Eurofins Scien tific SE (holding level)

� Main facilities in Eurofins Scientific SE:� OBSAAR bonds (issued in June 2010) : EUR 176m� Schuldschein (issued in July 2011) : EUR 170m� Eurobond (issued in November 2013) : EUR 300m� Bilateral RCF (drawn): EUR 188m

� EUR 25m of bank borrowings are secured over buildin gs and assets (in subsidiaries)

� In addition, EUR 300m Hybrid bond (considered equit y under IFRS), non-dilutive bond with perpetual maturity, callable at par by Eurofins in Jan 2020

Financing facility overview as of 30 June 2014

38


55.0

133.1

58.7

58.7

58.7

108.0 62.0

300.0

0.0

50.0

100.0

150.0

200.0

250.0

300.0

350.0

400.0

450.0

500.0

2015 2016 2017 2018

Bilateral credit lines (drawn) OBSAAR Schuldschein Eurobond

Maturity profile of senior debt at Holding level as of 30 June 2014

For private use only – Strictly confidential

Senior debt in Eurofins Scientific SE (EURm)

221.7

39

495.1


Tangible Commitment from Internal Stakeholders


� In July 2014, Eurofins issued118,820 warrants exclusively to its leaders

� Exercise Price €281.58

� Purchase Price €18.15

� Break-even Price €299.73

(in the money starting at €300)

� The warrants are not listed but gives access to new shares in Eurofins Scientific. The warrants are exercisable starting 01 July 2018, and valid for 10 years.

� Eurofins will have the right to accelerate the exercise of the warrants from July 2018 onwardsif the share price is above€506.84 (i.e. 180% of exerciseprice)

Upside/Downside for warrant holders

capital gain could becapped if exerciseacceleration istriggered by the company


41

�Food safety & contamination issues

�New regulations (e.g. FSMA, REACH)

�Outsourcing trend

�Risks due to globalisation of trade

�Vulnerability of global brands

�Scientific developments (e.g. GMOs, Biologics…. ) + new testing methods

Outlook: becoming the world leader in the bioanalyt ical testing market

�Unique technological portfolio of over 100,000 methods

�Volume scale advantage & Competence Centres

�Focus on running labs

�Global network of standardised labs

�Experience in integrating value adding acquisitions

�Recurring revenues with high switching costs and high barriers to entry

+ Key Success FactorsSustainable Market Growth Drivers

Eurofins’ unique position in a young, fast growing and fragmented market should lead to long term, sustainable profitability

= Solid Outlook



42

� Introduction




� Summary

� Appendix

Contents



Terms & Conditions of the contemplated bond issue

� Issuer: Eurofins Scientific S.E.

� Issue Rating: Not rated

� Issue Size: EUR [300 m] minimum

� Currency EUR

� Maturity [7] years

� Denomination: EUR100k+1k

� Listing: Luxembourg Stock Exchange

� Type: Senior Unsecured

� Documentation: Standalone / Change of Control / Mak e Whole / Clean-Up Call

� Global Coordinator: HSBC

� Joint Bookrunners: BNP Paribas / HSBC / SG CIB

For private use only – Strictly confidential 43


44

� Introduction




� Summary

� Appendix

Contents



45

High-growth, non-cyclical markets driven by secular

mega-trends

Advancing globalisation but with very few global

testing suppliers

Fragmented competition & opportunities for

consolidation

Very recurring business; 8% - 12% historic organic

growth

High barriers to entry

Best in class technology and quality give best brand

protection

No. 1 or 2 worldwide in most business lines

Strong international presence in 36 countries

State-of-the-art laboratory infrastructure

High switching costs for clients

Good cash flow visibility

Experienced multi-national leadership

Conclusion: our sustainable competitive advantage

� Track record of profitable growth – Strong ROCE and cash flow generation potential

� ROCE* of 14.7% and ROE** of 19.1% in 2013 despite significant future-orientated investments and one-off restructuring

costs

� 5-year CAGR: EPS 30.7%, Operating Cash Flow 23.0%

� Large potential to roll out business model in fast growing economies

� Following the last intense investment cycle (2006-2010), Eurofins is well-positioned to double in size and reach EUR

2bn in revenues by 2017 whilst maintaining leadership in multiple markets and improving profitability

*ROCE = EBITAS/Average Capital Employed over previous 4 quarters **ROE = Net Profit/Equity at the beginning of the year



46

Appendix / Back up slides



� 1: Adjusted results - reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”.� 2: Separately disclosed items - includes one-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs, temporary losses and other

costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring, non-cash accounting charges for stock options, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions and the related tax effects

EUR million Adjusted

Results 1

Separately

disclosed

items 2

Total Adjusted

Results 1

Separately

disclosed

items 2

Total

Revenues 643.5 643.5 570.3 570.3

Operating costs, net -534.5 -18.0 -552.5 -477.2 -14.8 -492.0

EBITDA 109.0 -18.0 91.0 93.1 -14.8 78.2

Depreciation and amortisation -32.7 -5.0 -37.7 -26.9 -4.5 -31.4

EBITAS 76.3 -23.0 53.2 66.2 -19.4 46.8

Non-cash stock option charges and

acquisition-related expenses, net

-7.1 -7.1 -5.3 -5.3

EBIT 76.3 -30.2 46.1 66.2 -24.7 41.5

Finance income 1.1 1.1 0.6 0.6

Finance costs -15.7 -15.7 -10.6 -10.6

Share of profit of associates 0.3 0.3 0.2 0.2

Profit before income tax 62.0 -30.2 31.8 56.4 -24.7 31.8

Income tax expense -13.0 3.7 -9.4 -11.1 1.7 -9.4

Net profit and loss for the period 48.9 -26.5 22.4 45.4 -23.0 22.4

Attributable to:

Equity holders of the Company 48.9 -26.4 22.6 45.2 -22.7 22.5

Non-controlling interests 0.0 -0.1 -0.1 0.2 -0.3 -0.1

Source: Eurofins H1 2014 Results

H1 2014 H1 2013

Consolidated Income Statement HY 2014 vs HY 2013

47


Consolidated Balance Sheet HY 2014 vs HY 2013

EUR million H1 2014 H1 2013 EUR million H1 2014 H1 2013

Property, plant and equipment 279.8 231.1 Total shareholders' equity 404.3 360.3

Goodwill 497.6 439.0

Other intangible assets 108.9 75.2 Borrowings 790.9 438.1

Others 52.7 47.2 Others 103.1 91.6

Total non-current assets 939.0 792.5 Total non-current liabilities 893.9 529.7

Inventories 23.7 19.9 Borrowings 73.2 60.9

Trade accounts receivable 289.9 251.2 Trade accounts payable 94.8 77.6

Cash and cash equivalents 378.4 117.5 Others 231.7 203.3

Others 62.5 46.2 Total current liabilities 399.7 341.8

Total current assets 754.4 434.7

Asset classified as held for sale 4.5 4.7

Total assets 1,697.9 1,231.8 Total liabilities 1,697.9 1,231.8

Source: Eurofins H1 2014 Results

48

Source presentation EDR: 1-C-IR-PRE-01187643Source modification date: 07/08/2014Source: Eurofins H1 2014 Results

EUR million H1 2014 H1 2013

Cash flows from operating activities

Profit before income taxes 31.8 31.8

Adjustments for:

Depreciation and amortisation 37.7 31.4

Change in net working capital -27.2 -5.4

Income tax paid -14.1 -14.6

Others 19.1 11.5

Net cash provided by operating activities 47.4 54.7

Cash flows from investing activities

Acquisition of subsidiaries, net of cash acquired -72.1 -57.3

Purchase of property, plant and equipment -44.9 -34.9

Purchase, capitalisation of intangible assets -12.6 -8.3

Procees from sale of property, plant and equipment 0.5 0.3

Change in investments and financial assets, net -1.4 -1.4

Dividends by Associates 0.1 0.0

Interest received 1.1 0.6

Net cash used in investing activities -129.3 -100.9

Cash flows from financing activitiesProceeds from issuance of share capital 1.7 5.2

Proceeds from borrowings 188.4 81.4

Repayments of borrowings -12.2 -29.0

Change in hybrid capital -9.0

Dividends to shareholders and non-controlling interests 0.0

Earnings paid to hybrid capital investors -10.5 -9.7

Interest paid -6.4 -7.7

Others 0.1 0.3

Net cash provided by financing activities 161.1 31.4

Net effect of currency translation on cash and cash equivalents and bank

overdrafts

-0.4 -1.6

Net increase (decrease) in cash and cash equivalents less bank overdrafts 78.9 -16.5

Cash and cash equivalents less bank overdrafts at beginning of period 293.3 122.2

Cash and cash equivalents less bank overdrafts at end of period 372.2 105.8

Consolidated Cashflow Statement HY 2014 vs HY 2013

49


� 1: Adjusted results - reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”.� 2: Separately disclosed items - includes one-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs, temporary losses and other

costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring, non-cash accounting charges for stock options, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions and the related tax effects

EUR million Adjusted

Results 1

Separately

disclosed

items 2

Total Adjusted

Results

Separately

disclosed

items

Total

Revenues 1,225.6 1,225.6 1,044.0 1,044.0

Operating costs, net -1,006.3 -30.2 -1,036.5 -867.5 -15.3 -882.7

EBITDA 219.3 -30.2 189.1 176.5 -15.3 161.2

Depreciation and amortisation -57.4 -9.5 -66.9 -45.4 -9.5 -54.8

EBITAS 161.9 -39.7 122.2 131.1 -24.7 106.4

Non-cash stock option charges and

acquisition-related expenses, net

-10.0 -10.0 -5.2 -5.2

EBIT 161.9 -49.7 112.2 131.1 -29.9 101.2

Finance income 1.1 1.1 1.5 1.5

Finance costs -24.6 -24.6 -21.2 -21.2

Share of profit of associates 0.3 0.3 0.2 0.2

Profit before income tax 138.7 -49.7 89.1 111.6 -29.9 81.7

Income tax expense -22.0 4.9 -17.2 -19.8 2.0 -17.8

Net profit and loss for the period 116.7 -44.8 71.9 91.8 -27.9 63.9

Attributable to:

Equity holders of the Company 116.8 -44.6 72.2 91.4 -25.4 65.9

Non-controlling interests -0.1 -0.2 -0.3 0.4 -2.5 -2.0

Source: Eurofins 2013 Annual Report

2013 2012

Consolidated Income Statement FY 2013 vs FY 2012

50


Consolidated Balance Sheet FY 2013 vs FY 2012

EUR million 2013 2012

Restated


Restated

Property, plant and equipment 251.1 209.3 Total shareholders' equity 394.7 372.0

Goodwill 456.4 402.7

Other intangible assets 86.4 69.0 Borrowings 666.9 383.0

Others 54.2 43.8 Others 96.7 88.5

Total non-current assets 848.0 724.8 Total non-current liabilities 763.6 471.6

Inventories 20.1 13.9 Borrowings 17.2 52.1

Trade accounts receivable 272.7 247.9 Trade accounts payable 101.0 77.8

Cash and cash equivalents 297.3 134.3 Others 220.5 187.1

Others 54.5 37.2 Total current liabilities 338.7 317.0

Total current assets 644.5 433.2

Asset classified as held for sale 4.4 2.5

Total assets 1,497.0 1,160.5 Total liabilities 1,497.0 1,160.5


51



Consolidated Cashflow Statement FY 2013 vs FY 2012

52


Cash flows from operating activities

Profit before income taxes 89.1 81.7

Adjustments for:

Depreciation and amortisation 66.9 54.8

Change in net working capital 13.8 -11.0

Income tax paid -30.5 -12.9

Others 30.1 21.6

Net cash provided by operating activities 169.3 134.2

Cash flows from investing activities

Acquisition of subsidiaries, net of cash acquired -87.4 -79.3

Purchase of property, plant and equipment -79.2 -58.4

Purchase, capitalisation of intangible assets -20.3 -13.3

Procees from sale of property, plant and equipment 0.8 7.1

Change in investments and financial assets, net -4.0 -1.9

Interest received 1.1 1.5

Net cash used in investing activities -189.0 -144.3

Cash flows from financing activities

Proceeds from issuance of share capital 8.0 24.4

Proceeds from borrowings 325.3 11.7

Repayments of borrowings -83.7 -32.7

Change in hybrid capital -9.1 0.0

Dividends to shareholders and non-controlling interests -15.5 -12.1

Earnings paid to hybrid capital investors -9.7 -12.1

Interest paid -21.4 -19.9

Net cash provided by financing activities 194.0 -40.7

Net effect of currency translation on cash and cash equivalents and bank

overdrafts

-3.2 -0.8

Net increase (decrease) in cash and cash equivalents less bank overdrafts 171.1 -51.5

Cash and cash equivalents less bank overdrafts at beginning of period 122.2 173.7

Cash and cash equivalents less bank overdrafts at end of period 293.3 122.2


Eurofins has vastly outperformed the market since its IPO and each of its 3 equity offerings (based on share price of EUR 212.05 as of 31 December 2014)

1997 € 5m

1998rights issue€ 6m

SPO 1

1999rights issue€ 7m

SPO 2

2000 SPO

€ 38.5m

SPO 3

Eurofins: +11,484% (32% CAGR)CAC 40: +54% (3% CAGR)SBF 120: +78% (3% CAGR)

S&P 500: +135% (5% CAGR)

Eurofins: +2,593% (23% CAGR)CAC 40: +20% (1% CAGR)SBF 120: +39% (2% CAGR)S&P 500: +93% (4% CAGR)

Eurofins: +2,670% (25% CAGR)CAC 40: -9% (-1% CAGR)SBF 120: 5% (0% CAGR)

S&P 500: +59% (3% CAGR)

Eurofins: +393% (12% CAGR)CAC 40: -32% (-3% CAGR)SBF 120: -20% (-2% CAGR)S&P 500: +49% (3% CAGR)

Eurofins: +1166% (29% CAGR)CAC 40: +12% (1% CAGR)SBF 120: +24% (2% CAGR)S&P 500: +70% (5% CAGR)

10 years

Since SPO 2

Since SPO 1

Since IPO

Since SPO 3

2 years

Eurofins: +73% (32% CAGR)CAC 40: 17% (8% CAGR)

SBF 120: 20% (10% CAGR)S&P 500: +44% (20% CAGR)

5 yearsEurofins: +455% (41% CAGR)

CAC 40: 9% (2% CAGR)SBF 120: 18% (3% CAGR)

S&P 500: +85% (13% CAGR)

Total equity raised in 4 offerings: only EUR 56m

53

IPO


Eurofins has generated comparable organic growth to its larger peers which have deeper footprint in fast-growing emerging markets and in cyclical areas

Source: Eurofins, Company websites

In spite of its lower cyclicality, Eurofins generat es comparable organic growth to its larger peers in ea ch cycle, and higher growth when the economy slows

H1 2014

TICS ex ERF = SGS, Intertek, Bureau Veritas* Includes 2% organic growth consensus estimate for Bureau Veritas for H1 2014

54


We have built a hard-to-replicate world-class infrastructure

Eurofins has been consistently investing more than its peers

Source: Eurofins, Company reports

0%

10%

20%

30%

40%

50%

60%

70%

80%

0%

1%

2%

3%

4%

5%

6%

7%

8%

9%

00-'04 05-'08 09-'10 2010 2011 2012 2013

Exc

ess

In

ve

stm

en

t

Ca

pe

x to

Sa

les

ERF TICS ex ERF Excess investment

TICS ex ERF = SGS, Intertek, Bureau Veritas

55


56

Post acquisition and integration into Eurofins, bot h sales and profits increase significantly

Illustration

0.0

1.0

2.0

3.0

4.0

5.0

6.0

7.0

1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004

Annual Sales / million

Acquired by

Eurofins

CAGR19%

EBITA margin in % of sales

<8% >20%

Growth drivers post acquisition:

1) Sales increase through cross selling of Eurofins lab specialities internationally

2) Cost reduction – focus on most frequently performed tests

Frequency(e.g. no. of

tests per day)

No. of tests offered

100

Prior to acquisition

50% 50%% of employees performing tests

Can be subcontracted to specialised Eurofins laboratories after acquisition

400

Focus and scale drive profitability

Actual example of an acquired lab:

100

50

500

Company A


eurofins corporate december 2014 hva debt investor · 2017-07-18 · eurofins a global leader in...

Documents